Merck Expands Hematology Portfolio with $6.7B Acquisition of Terns Pharmaceuticals
- Mar 25
- 1 min read
Rahway, NJ and Foster City, CA, March 25, 2026 (Business Wire) -- Merck has agreed to acquire Terns Pharmaceuticals in an all-cash transaction valued at approximately $6.7 billion. The deal adds TERN-701, an investigational oral therapy for chronic myeloid leukemia, to Merck’s oncology pipeline. The transaction is expected to close in the second quarter of 2026, pending customary conditions.
Read full article here.
Comments